Related Experiment Video
Updated: May 31, 2025
07:47
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
Published on: August 31, 2022
2.2K
CHROMOPHOBE HEPATOCELLULAR CARCINOMA: DIAGNOSTIC CHALLENGES
Sana Ben-Slama1,2, Ines Mallek1, Eya Ghorbeli3
1Mongi Slim Hospital, Department of Pathology - Marsa, Tuni, Tunísia.
Summary
Chromophobe hepatocellular carcinoma (CHCC) is a rare liver cancer variant. Identifying its unique molecular features, like alternative lengthening of telomeres, aids diagnosis and potential targeted therapies.
Area of Science:
- Hepatobiliary pathology
- Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) includes rare variants such as chromophobe hepatocellular carcinoma (CHCC).
- CHCC exhibits distinct histological and molecular characteristics differentiating it from conventional HCC.
- Understanding these variants is crucial for accurate diagnosis and patient management.
Purpose of the Study:
- To present a case of chromophobe hepatocellular carcinoma (CHCC).
- To highlight the diagnostic challenges associated with rare HCC variants.
- To discuss the potential of molecular markers in diagnosing and treating CHCC.
Main Methods:
- Case report of a 56-year-old male with chronic hepatitis C presenting with a liver lesion.
- Histopathological examination of the resected liver tumor, including macroscopic and microscopic analysis.
- Review of diagnostic criteria and molecular features relevant to CHCC.
Main Results:
- The final diagnosis of the liver lesion was chromophobe hepatocellular carcinoma (CHCC).
- CHCC presents diagnostic challenges due to overlapping features with other hepatic tumors.
- The alternative lengthening of telomeres (ALT) phenotype may serve as a distinguishing molecular marker for CHCC.
Conclusions:
- Accurate recognition of rare HCC variants like CHCC is essential for effective clinical management.
- Further research into the clinical behavior and therapeutic responses of CHCC is warranted.
- Molecular testing, including ALT phenotype identification, may improve CHCC diagnosis and guide targeted therapies.
